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Abstract: This review summarizes Phase III clinical trial data available for fingolimod. The 
main purpose is to evaluate the benefit-risk profile of fingolimod, the first oral compound 
available for treatment of multiple sclerosis (MS) and just recently approved by the European 
authorities. The authors place this evaluation in the context of the known safety and efficacy 
profile of established compounds for therapy of MS to outline the current and future potential 
of fingolimod. The authors conclude that only long-term safety data from post-marketing 
surveillance plans, together with additional head-to-head studies, would allow evidence-based 
treatment decisions. Furthermore, risk-profile analyses including patient history, exposure 
data to certain pathogens, and genetic analyses may potentially help to choose the right drug 
for individual patients in the future. Until these approaches toward an individualized medicine 
have been validated, treatment decisions for one or the other compound will have to be based 
partly on class IV evidence. Therefore, a close dialog with the well-informed patient, secured 
by effective risk mitigation plans, is required to choose the compound.
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Introduction
Multiple sclerosis (MS) is a chronic and debilitating immune-mediated disease of the 
central nervous system (CNS). Recent epidemiological data supports the established 
view that the incidence of MS peaks at about 30 years of age and that it is a disease 
with a positive female-to-male ratio.1 Widespread axonal pathology has already been 
reported in early stages of MS, including clinically isolated syndrome (CIS).2,3 Thus, 
treatment initiation at an early stage in the disease seems crucial; this is supported by 
positive clinical trial data for first-line disease-modifying drugs (DMDs) in delaying 
conversion of CIS to MS in patients.4 Paraclinical surrogate parameters are currently 
under investigation to predict disease progression and conversion from CIS to MS, 
including magnetic resonance imaging (MRI) criteria at initial presentation and the 
presence of oligoclonal bands or levels of CXCL-13 in cerebrospinal fluid (CSF).3–5 
However, these surrogates are not yet able to predict the future grade of disability on 
an individual basis with certainty.6 In the European Union (EU), the three different 
interferon-beta (IFNβ) formulations available, as well as glatiramer acetate (GA), are 
considered as first-line treatments based on class I evidence for similar efficacy and a 
positive safety profile.7 Recent head-to-head studies did not detect differences in the 
primary endpoints between IFNβ and GA. When selecting a treatment from among 
these injectable drugs, individual decisions will be based mainly on the preferred route Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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of application (subcutaneous or intramuscular [IM]) and the 
individual tolerability of the compound used.
Until recently, natalizumab was the established second 
choice for patients failing first-line DMDs. In addition, it has 
been approved as a primary treatment for patients with highly 
active relapsing-remitting MS (RRMS). Natalizumab is a 
humanized monoclonal IgG4 antibody, designed to target the 
alpha-4 integrin, and is most relevant for leukocyte migration 
across endothelial barriers.8,9 Class I evidence is available for 
superiority regarding clinical outcome measures of natalizumab 
compared with placebo and for the combination of natali-
zumab and IM IFNβ-1a compared with IM IFNβ-1a alone.10,11 
  However, no class I evidence is available directly comparing 
efficacy of natalizumab with first-line DMDs. When looking 
at the efficacy of natalizumab and first-line DMDs across 
different clinical trials on clinical outcome measures such as 
the annualized relapse rate (ARR), the data available suggest 
superiority of natalizumab; this is supported by clinical experi-
ence (class IV evidence).4 Therefore, restricted approval as a 
second-line treatment is not explained by inferiority compared 
with first-line DMDs or by study design of trials relevant for 
approval; it is explained mainly by the occurrence of cases of 
progressive multifocal leukoencephalopathy (PML) in around 
1/1000 patients treated with natalizumab.12–15 The risk of 
this potentially lethal or highly disabling adverse event (AE) 
increases to up to 8.1/1000 patients (95% confidence interval: 
5.4–11.6/1000 patients) among a subset of patients with prior 
immunosuppressant treatment who have been treated with 
natalizumab for more than 2 years, and who show evidence of 
JC virus exposure as assessed by JC virus serology.16
Furthermore, mitoxantrone was licensed in 2002 for 
treatment of patients with secondary progressive MS or 
where progressive relapsing MS is failing or not tolerating 
previous immunomodulatory therapy.7 However, the risk of 
cardiomyopathy and secondary leukemia, overall observed 
in 1/250 to 1/800 patients treated, limits the use of this drug 
and makes it a third-line treatment for patients with relaps-
ing forms of MS.7
On September 22, 2010, the US Food and Drug 
Administration approved fingolimod 0.5 mg, a sphingosine 
1-phosphate (S1P) receptor modulator, as the first oral medi-
cation for treatment of RRMS.17 In March 2011, the European 
Medicines Agency (EMA) approved fingolimod in Europe. 
However, the European authorities restricted the approval to 
patients with high disease activity despite treatment with IFNβ 
(nonresponder) and to patients with rapidly evolving RRMS.18 
The EMA defined nonresponders to IFNβ as those having 
failed to respond to “normally at least one year of treatment of 
IFNβ.”18 According to EMA recommendations, these patients 
should have experienced a minimum of one relapse in the pre-
vious year while on IFNβ, and at least nine T2-hyperintense 
lesions in cranial MRI or at least one gadolinium-enhancing 
lesion, or should have had an “unchanged or increased relapse 
rate or ongoing severe relapses, as compared to the previous 
year.”18 The second group of patients with rapidly evolving 
severe RRMS was defined “by 2 or more disabling relapses in 
1 year, and with one or more Gadolinium enhancing lesions 
on brain MRI or a significant increase in T2 lesion load as 
compared with a previous recent MRI.”18
Thus, a restricted approval in the EU is given for two com-
pounds, natalizumab and fingolimod, available for the same 
indication: first-line therapy for highly active MS or second-line 
therapy in patients not tolerating or not responding to first-line 
DMDs. In this review, the authors give an overview of clinical 
trial efficacy and safety data available that is relevant for the 
approval of fingolimod by the US and the European authorities; 
the authors then evaluate the current and future potential of 
fingolimod within the treatment algorithms for MS.
Fingolimod and its mode of action
The molecular structure of fingolimod is shown in Figure 1. 
Fingolimod is derived from myriocin, which has been primar-
ily isolated from Isaria sinclairii, a fungus used in traditional 
herbal medicine.19 Fingolimod is predominately metabolized 
in the liver by sphingosine kinase to the active metabolite 
fingolimod-phosphate.20 Knock-out studies in S1P receptor-
deficient mice suggest S1P receptors as key receptors relevant to 
the therapeutic effects in experimental autoimmune encephalitis, 
an animal model of MS. Accordingly, fingolimod-phosphate 
binds to four of the five known S1P receptors: S1P1, S1P3, S1P4, 
and S1P5. Expression of these receptors varies throughout tis-
sues, being differently expressed on lymphocytes, in various 
different peripheral organs, and cells of the CNS or the periph-
eral nervous system.21 Coupling to G proteins, S1P receptors 
regulate complex processes such as growth and survival, cell 
motility, cell invasion, angiogenesis, and trafficking of immune 
cells. Upon binding (eg, to the membrane-bound cell surface 
S1P1 receptor) fingolimod-phosphate induces internalization of 
OH
OH
NH2
Figure 1 The chemical structure of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]
propan-1,3-diol hydrochloride).Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the receptor, which then leads to a sustained downregulation 
of the receptor on the gene expression level.22,23 In lymphatic 
tissue, fingolimod-phosphate thereby blocks the capacity of 
certain subpopulations of lymphocytes to egress lymph nodes, 
causing redistribution, rather than depletion, of lymphocytes. 
The redistribution of certain lymphocyte subpopulations is 
considered to reduce the infiltration of pathogenic cells into 
the CNS and to mediate the main therapeutic effect on the 
clinical course of MS. Naïve and memory T-cells, expressing the 
chemokine receptor CCR7 on their surface, are preferentially 
retained. In contrast, effector memory T-cells, which are capable 
of downregulating their surface CCR7, are less dependent on 
S1P signaling and thus are considered to preserve important 
immunological functions for antiviral or antineoplastic 
defense.21 In addition to reducing infiltration of pathogenic 
cells into the CNS, a direct neuroprotective and regenerative 
potential of fingolimod has been extensively discussed in recent 
literature. Fingolimod-phosphate is highly protein bound and is 
able to cross the blood–brain barrier. Thus, it could potentially 
directly interact with receptors on neurons and glia cells, and 
mediate the neuroregenerative effects proposed to be associated 
with fingolimod treatment.22 However, many of these immuno-
logical data derive from rodent models,24,25 and expression of 
S1P receptors in a variety of different tissues may mediate not 
only its therapeutic but also its adverse effects so far observed 
in clinical trials. Overall, the lymphocyte count decreases to 
approximately 60% of baseline within 4–6 hours after the first 
dose, with normal counts usually reached within 1–2 months 
after treatment discontinuation.20
Pharmacokinetics of fingolimod
The oral bioavailability of fingolimod is 93% and the average 
terminal half-life is 6–9 days.20 As fingolimod is primarily 
metabolized by hepatic enzymes of the CYP family (mainly 
CYP4F2), inhibitors or inducers of these isozymes alter the 
exposure of fingolimod or fingolimod-phosphate. Patients 
with severe hepatic dysfunction should be closely monitored 
when receiving fingolimod as the risk of adverse reactions 
is potentially higher.20
Efficacy of fingolimod in Phase III  
clinical trials
Fingolimod vs placebo
Study design
Patients 18–55 years of age with RRMS26 and a score from 
0 to 5.5 on the Expanded Disability Status Scale (EDSS)27 
were eligible for the FTY720 Research Evaluating Effects 
of Daily Oral therapy in Multiple Sclerosis (FREEDOMS) 
double-blind clinical trial, which aimed to assess the efficacy 
of two different doses of oral fingolimod compared with 
placebo for 24 months.28 Prior to randomization, patients 
were required to have an active course of disease (one or 
more relapses in the previous year or two or more in the 
previous 2 years) and IFNβ or GA was to be stopped at least 
3 months before the trial. Randomization was conducted in 
a 1:1:1 ratio to the high-dose (fingolimod 1.25 mg) or the 
low-dose (fingolimod 0.5 mg) treatment group or to placebo, 
each administered once daily. The primary clinical outcome 
measure was the ARR, defined as the number of confirmed 
relapses per year. A confirmed relapse needed to be associ-
ated with an increase of at least 0.5 points in the EDSS score, 
1 point in each of two EDSS functional system (FS) scores, 
or 2 points in one EDSS FS score. The key secondary clinical 
outcome measure was time to confirmed disability progres-
sion after 3 months, as measured in an increase of 1 point 
in the EDSS score (or 0.5 points if the baseline EDSS score 
was 5.5) confirmed after 3 months.28 In addition, clinical 
endpoints (time to first relapse, time to disability progression 
after 6 months, changes in the EDSS score and the Multiple 
Sclerosis Functional Composite z-score between baseline 
and 24 months) and paraclinical endpoints (number of gad-
olinium-enhancing lesions, proportion of patients free from 
gadolinium-enhancing lesions, number of new or enlarged 
lesions on T2-weighted MRI scans, proportion of patients 
free from new or enlarged lesions on T2-weighted scans, 
volumes of hyperintense lesions on T2-weighted scans and 
hypointense lesions on T1-weighted scans, change in brain 
volume between baseline and 24 months) were assessed.28
Study results
In a total of 1033 patients completing the 24-month study, 
all clinical and paraclinical endpoints demonstrated superi-
ority for both the low and the high dose of fingolimod over 
placebo. No significant differences in efficacy were observed 
when comparing the two different doses of fingolimod. 
Interestingly, the overall ARR observed in the fingolimod 
Phase III clinical trials was low compared with studies 
relevant for approval of interferons, for example. Thus, 
although the absolute reduction of the ARR appeared to be 
low, the relative reduction of the ARR (primary endpoint: 
0.18 for fingolimod 0.5 mg; 0.16 for fingolimod 1.25 mg; 
0.40 for placebo) compared with placebo was 54% and 60%, 
respectively (Figure 2), independent of previous treatment 
with other DMDs.28 In addition, the percentage of patients 
without relapse was around 70% in the fingolimod 0.5 mg 
group and 75% in the fingolimod 1.25 mg group, compared Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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with 46% in the placebo group. The key secondary outcome 
measure, the time to disability progression, confirmed after 
3 months, demonstrated a hazard ratio for the risk of dis-
ability progression of 0.70 for the 0.5 mg dose and 0.68 
for the 1.25 mg dose compared with placebo, showing that 
fingolimod may be able to delay disability progression. All 
paraclinical outcome measures were in favor of both of the 
treatment groups compared with placebo, including surro-
gates for inflammatory activity or scar formation on MRI (eg, 
number of contrast-enhancing lesions or number of new or 
enlarged lesions on T2-weighted scans), as well as measures 
for tissue loss (eg, change in volume of hypointense lesions 
on T1-weighted images or change in brain volume).28
Fingolimod vs iFNβ
Study design
A 12-month, multicenter, randomized, double-blind, head-
to-head core study (Trial Assessing Injectable Interferon 
vs FTY720 Oral in Relapsing-Remitting Multiple Sclero-
sis [TRANSFORMS]) assessed the efficacy and safety of 
fingolimod compared with IM IFNβ-1a.29 Patients were 
randomized to receive either the high or the low dose of 
oral fingolimod once daily or IM IFNβ-1a once a week as 
active comparator. The study was performed in a double-
dummy fashion, with all patients receiving matching placebo 
in addition to the active treatment to ensure blinding. In a 
12-month extension of the TRANSFORMS study, patients 
originally assigned to receive the high or the low dose of 
fingolimod continued with the same treatment, whereas 
patients originally receiving IFNβ-1a were re-randomized 
to either the high or the low dose of fingolimod.30 Inclusion 
criteria and definitions of outcome measures were similar 
to those described for the FREEDOMS study. The primary 
endpoint was the ARR. Time to confirmed disability pro-
gression and the number of new or enlarged hyperintense 
lesions on T2-weighted MRI scans were key secondary 
outcome measures.29
Study results
A total number of 1153 patients completed the core study, 
whereas 882 patients completed the total of 24 months on 
treatment including the extension phase. The primary out-
come measure after 12 months showed superiority of both 
doses of fingolimod compared with IM IFNβ-1a: there was a 
significantly greater reduction in the ARR (primary endpoint: 
0.16 for fingolimod 0.5 mg; 0.20 for fingolimod 1.25 mg; 
0.33 for IM IFNβ-1a), with a relative reduction compared 
with IFNβ-1a of 52% and 38%, respectively (Figure 3).29 
Furthermore, patients initially randomized to receive IM 
IFNβ-1a in the core study demonstrated a lower ARR after 
switching to fingolimod (IFNβ-1a to fingolimod 0.5 mg: 
ARR 0.31 [first year] vs 0.22 [second year]; IFNβ-1a to 
fingolimod 1.25 mg: ARR 0.29 [first year] vs 0.18 [  second 
year]). The percentage of patients without relapse was 83% 
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Figure 2 Annualized relapse rate (ARR) from baseline to month 24 in the FTY720 
Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS) 
study.28
Notes: The percentages indicate the relative reduction of the ARR of fingolimod 
compared with placebo. Modified from Kappos L, Radue EW, O’Connor P, et al.   
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J 
Med. 2010;362(5):387–401.28
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Figure 3 Annualized relapse rate (ARR) from baseline to month 12 in the Trial 
Assessing  Injectable  Interferon  vs  FTY720  Oral  in  Relapsing-Remitting  Multiple 
Sclerosis (TRANSFORMS) study.29
Notes: The percentages indicate the relative reduction of the ARR of fingolimod 
compared with intramuscular interferon-beta-1a (IFNβ1a). Modified from Cohen JA, 
Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing 
multiple sclerosis. N Engl J Med. 2010;362(5):402–415.29Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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after 12 months in patients treated with fingolimod 0.5 mg, 
80% for the fingolimod 1.25 mg group, and 69% in the 
placebo group. In contrast to the FREEDOMS study, the 
TRANSFORMS study failed to show beneficial effects on 
disability progression. As TRANSFORMS was not designed 
to primarily demonstrate the beneficial effect of fingolimod 
on disability progression, this discrepancy could potentially 
be explained by the TRANSFORMS study being under-
powered with an active comparator and a very low propor-
tion of patients with disability progression overall in the 
study cohort. Regarding MRI outcome measures, patients 
in the two fingolimod groups demonstrated fewer new or 
enlarged hyperintense lesions on T2-weighted images at 
month 12 (mean: 1.7 for fingolimod 0.5 mg; 1.5 for fingoli-
mod 1.25 mg; 2.6 for   placebo). Whereas the mean percent 
reduction in brain volume from baseline to 12 months was 
significantly reduced for the fingolimod groups, changes in 
the volume of lesions on unenhanced T2- or T1-weighted 
images at 12 months were similar among the different 
study arms.29 In this respect the results again differ from the 
  FREEDOMS study data, most likely attributed to a lack of 
power as discussed for the disability progression.
Ongoing phase iii and iv clinical trials
Currently, the search on ClinicalTrials.gov for the terms 
“fingolimod AND multiple sclerosis” lists 14 ongoing or 
planned clinical trials (Table 1).31 Among these, the exten-
sion trials, as well as post-marketing surveillance studies 
including a pregnancy registry, focus on long-term efficacy 
and safety of the approved low dose of fingolimod. The 
FTY720 in Patients With Primary Progressive Multiple 
Sclerosis study evaluates the efficacy of fingolimod in 
patients with primary progressive MS, and additional studies 
focus on biomarker changes during fingolimod treatment, 
the immune response during vaccination, or the beneficial 
effect of fingolimod on cognitive function compared with 
IFNß-1a (Table 1).
Safety and tolerability of fingolimod
Most of the safety data available derive from the two com-
pleted Phase III clinical trials, FREEDOMS and TRANS-
FORMS. Upper respiratory tract infections, headache, 
fatigue, nausea, and gastrointestinal dysfunction were among 
the most frequently observed AEs.28,29 As in previous clini-
cal trial experience, dose-dependent decreases in the heart 
rate commencing 1 hour after the first dose of fingolimod 
were observed; thus, bradycardia and atrioventricular 
block were more frequently reported in patients receiving 
fingolimod than in controls.28,29 Therefore, according to the 
manufacturer’s recommendations, patients are required to 
be observed for signs and symptoms of bradycardia for at 
least 6 hours after administration of the first dose. However, 
a recent report of a patient with MS who developed a delayed 
7.5-second asystole and sustained bradycardia 21 hours 
after the first dose of fingolimod stresses the importance of 
cardiac monitoring during treatment initiation.32 This is of 
particular importance if additional risks for cardiac conduc-
tion abnormalities exist, such as risperidone comedication 
in the latter case mentioned.32 Within the clinical trials, 
the therapeutic low dose of fingolimod caused an increase 
of approximately 2 mmHg systolic and 1 mmHg diastolic 
blood pressure. Thus, blood pressure should be monitored 
throughout treatment with fingolimod.
Three deaths occurred in the FREEDOMS study: two in 
the placebo group (pulmonary embolism, traffic accident) and 
one in the high-dose fingolimod group (suicide).   However, 
in the TRANSFORMS study, the two deaths observed 
both occurred in the high-dose fingolimod group: one due 
to disseminated primary varicella zoster infection (with 
corticosteroids as concomitant medication) and the other 
due to herpes simplex encephalitis. Two additional patients 
of this study arm died after the study (aspiration pneumo-
nia, metastatic breast cancer). Infections were reported 
equally throughout the groups (69%–72% for FREEDOMS, 
51%–53% for TRANSFORMS), with serious infections 
in 1.6%–2.6% and 0.2%–1.7% of patients, respectively. 
  Bronchitis and pneumonia were more common in patients 
treated with fingolimod.28,29
Macular edema in patients treated with low-dose fingoli-
mod occurred in 0.5% of patients in the TRANSFORMS 
study but did not occur for this dose in the FREEDOMS 
study. However, macular edema was more frequently 
observed in the high-dose fingolimod group (1% and 0.7%, 
respectively). Patients with diabetes mellitus or history 
of uveitis seem to be at increased risk. Macular edema 
improved or resolved with or without treatment in most of 
the patients when the drug was discontinued. Nevertheless, 
some patients had residual visual acuity loss even after 
resolution.28,29
Modest dose-dependent reductions in forced expiratory 
volume over 1 second (FEV1) and diffusing capacity of the 
lung for carbon monoxide were observed in patients treated 
with fingolimod, requiring spirometric evaluation if clinically 
indicated.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Increases in liver enzymes such as alanine aminotrans-
ferase were more frequently observed in the treatment 
groups of the FREEDOMS and TRANSFORMS studies 
(8.5% and 8%, respectively, for fingolimod 0.5 mg; 12.5% 
and 7%, respectively, for fingolimod 1.25 mg; 1.7% for 
placebo; 2% for IFNβ).28,29 In general, serum transaminase 
levels returned to normal within 2 months after treatment 
discontinuation.
Oral carcinogenicity studies in mice and rats with doses 
higher than the equivalent recommended human dose resulted 
in an increased incidence of malignant lymphomas.20 Malig-
nancies occurring in patients treated with fingolimod within 
the FREEDOMS and TRANSFORMS core studies were 
basal cell carcinoma (ten cases in total), breast cancer (five 
cases), malignant melanoma (two cases), and Bowen’s disease 
(one case); however, overall occurrence of malignancies did 
not differ between the fingolimod-treated patients and the 
control groups.
Data on teratogenicity and embryolethality in humans is 
limited, but fetal malformations including persistent truncus 
arteriosus and ventricular septal defect were observed in 
rats. Within the Phase II and III clinical trials, 47 pregnan-
cies occurred and 15 healthy children were born.33   However, 
one case of tibia malformation was reported, five spontane-
ous abortions occurred, and 14 patients decided to undergo 
elective abortion (among these, one case of tetralogy of 
Fallot was seen). Acrania was detected by ultrasonography 
in one of the twelve pregnancies reported as still ongoing.33 
Thus, due to the calculated elimination time, women of 
childbearing potential have to use effective contraception 
during and for 2 months after treatment discontinuation.20 
In addition, a pregnancy registry has been initiated to 
monitor outcomes of pregnancies in patients treated with 
fingolimod.
Conclusion and perspective: 
potential of oral fingolimod  
in treatment of MS
There are obvious reasons why the approval of fingolimod 
should be highly appreciated by MS patients and their 
physicians: First, in one head-to-head clinical trial,29 fingoli-
mod has been proven to be superior to approved first-line 
DMDs as regards efficacy. This seems to hold true also for 
patients initially treated with IM IFNβ-1a and then switched 
to fingolimod.30 This is of particular relevance, as this will 
mimic clinical practice when fingolimod is given as a second-
line treatment.34 Second, oral administration could potentially 
further improve treatment acceptance in patients (no evident 
lifestyle restrictions, no further self-injections with local 
adverse effects or flu-like symptoms, no risk of developing 
Table 1 Ongoing Phase II–IV clinical trials: summary of ClinicalTrials.gov search results for the terms “fingolimod AND multiple 
sclerosis,” selecting only ongoing or planned studies31
Study Phase Fingolimod  
treatment  
(mg)
Comparator Primary outcome  
measure
Population Date results  
expected
ClinicalTrials. 
gov ID
FReeDOMS ii iii  0.5, 1.25 Placebo Safety and efficacy RRMS March 2011 NCT00355134
iNFORMS iii 0.5, 1.25 Placebo Safety and efficacy PPMS December 2013 NCT00731692
extension  
trials
ii + iii 0.5 NA Long-term safety  
and efficacy
RRMS February 2011– 
April 2014
NCT01201356, 
NCT00662649, 
NCT00670449, 
NCT00235430, 
NCT01127750
Post-marketing  
surveillance
Observ 0.5 NA Long-term safety  
and efficacy
RRMS December 2018 NCT01281657
ePOC iv 0.5 Standard care Outcome and safety RRMS June 2012 NCT01216072, 
NCT01317004
Biomarker iii 0.5 NA Changes in immunological  
biomarkers
RRMS December 2011 NCT01310166
vaccination iii 0.5 NA immune response to  
seasonal flu vaccination
RRMS May 2011 NCT01199861
Pregnancy  
registry
iii 0.5, 1.25 NA Pregnancy outcome RRMS April 2017 NCT01285479
GOLDeN iii 0.5 iFNß-1b Cognitive symptoms RRMS June 2013 NCT01333501
Abbreviations: ePOC, A 6 month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod 0.5 mg/Day vs. Comparator in Patients With 
Relapsing Forms of Multiple Sclerosis; FREEDOMS II, FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis; GOLDEN, Fingolimod Versus IFN Beta 
1b in Cognitive Symptoms; ID, identifier; IFNβ, interferon-beta; INFORMS, FTY720 in Patients With Primary Progressive Multiple Sclerosis; NA, not applicable; Observ, 
observational; RRMS, relapsing-remitting multiple sclerosis; PPMS, primary progressive multiple sclerosis.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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antidrug antibodies). This could increase the compliance rate 
with an additional positive effect on long-term outcome in 
the individual patient.35
However, as a new compound without any post-marketing 
experience from other fields or conditions, only long-term 
surveillance data after approval will allow us to judge the 
future position of fingolimod within the current treatment 
regimens for MS.
The following two key questions are still to be answered 
before the treating neurologist is able to make   evidence-based 
decisions: (1) Has fingolimod a positive benefit-risk ratio 
compared with the established first-line DMDs such as 
IFNβ or GA? or, in other words, considering the situation 
in the US: Can fingolimod equally be offered to the young 
and otherwise healthy patients of childbearing potential? 
(2) Considering the approval in the EU: which compound 
to choose for patients with highly active MS or patients not 
tolerating or not responding to first-line DMDs, natalizumab, 
or fingolimod?
With regard to the first question, we learned from 
natalizumab that phase III clinical trials are unable to 
predict the risk of rare complications such as PML. Tar-
geting lymphatic S1P1 receptor is considered to preferen-
tially target naïve and central memory T-cells, sparing the 
effector memory T-cell population.36 This could potentially 
result in a selective mode of action targeting autoimmunity 
and preserving key responses of the adaptive immunity 
relevant for viral defence.37 However, these concepts and 
treatment rationales still have to be confirmed by data 
from the post-marketing period. The first data available on 
changes to the immune response and cellular composition 
of peripheral blood and CSF from patients in clinical trials 
indicate not only significant peripheral cell depletion in 
patients treated with fingolimod but also potential changes 
to the immune surveillance in the CNS; fingolimod seems 
to decrease the absolute cell counts in CSF compared 
with pretreatment values, but it also leads to a reversion 
of the CD4:CD8 ratio in the CSF,38 a finding discussed 
previously as having potential relevance to the PML 
pathogenesis in MS patients treated with natalizumab.39 
Vaccination studies imply that these changes to the adap-
tive immunity may be of clinical relevance; although a 
recent study was not suggestive for relevant differences 
of the humoral immune response to influenza vaccines in 
patients treated with fingolimod compared with placebo,40 
data from studies involving healthy volunteers treated with 
fingolimod 0.5 mg assessing immunogenicity of keyhole 
limpet hemocyanin and the 23-valent pneumococcal 
polysaccharide vaccine indicate a decrease of antigen-
specific IgM titers by 91% and 25%, respectively, and of 
IgG titers by 45% and 50%, respectively.20 Therefore, the 
observation of serious herpes virus infectious complica-
tions in the TRANSFORMS study leading to death in 
two cases may not be by chance,29 although causality to 
the treatment with fingolimod still has to be established. 
Furthermore, data on teratogenicity is limited and although 
effective contraceptive measures are mandatory during 
and for 2 months after treatment discontinuation, cases 
of pregnancy in this cohort of patients will most likely 
occur, with uncertain consequences for the unborn child. 
So, will the benefits outweigh the risks in a long-term 
perspective of several decades of treatment in the indi-
vidual patient? The honest answer is this is not known 
yet. However, the established safety profile of long-term 
IFNß or GA treatment is known. Therefore, in the authors’ 
opinion, these issues will need to be discussed with the 
well-informed patient before considering fingolimod as a 
first-line choice in treatment of MS.
On the grounds of these considerations, the authorities 
in the EU restricted the approval of fingolimod to cases of 
highly active MS or patients not tolerating or not responding 
to first-line DMDs. However, this leads to a situation of two 
compounds approved in the EU for the same   indication: 
natalizumab and fingolimod. Both have been proven to be 
highly effective, although direct comparative head-to-head 
clinical trials have not yet been undertaken. So, in regard to 
the second key question – which compound to choose for 
this indication, natalizumab or fingolimod? – again, the final 
decision will be based on benefit-risk considerations in the 
individual patient. The first prerequisite for an evidence-
based decision for the individual is head-to-head clinical 
trials comparing the two compounds in efficacy. While 
these should be performed, they most likely will never be 
conducted. While only post-marketing experience will be 
able to demonstrate the safety profile of fingolimod, first 
attempts to stratify patients at risk of PML treated with 
natalizumab are on the way. These approaches may in the 
future lead toward an individualized medicine, where data 
from a patient’s history, genetic factors such as HLA status, 
functional measures for the innate and adaptive immunity, 
and exposure to specific infectious agents (such as JC virus 
serology) could be taken into account to find the best treat-
ment for the individual patient. Until these promising future 
tools are validated and have been proven to be applicable 
in daily clinical practice, the correct individual treatment 
decisions can only be found in dialog with the well-informed Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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patient, supported by high standards of post-marketing safety 
surveillance programs.
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